within Pharmacolibrary.Drugs.ATC.R;

model R01BA53
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.38,
    Cl             = 28.333333333333332,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.2,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0030833333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Phenylephrine, used as a nasal decongestant, is often combined with other agents (such as antihistamines or analgesics) to treat symptoms of common cold or allergic rhinitis. It acts as a selective alpha-1 adrenergic receptor agonist, leading to vasoconstriction and reduction of nasal congestion. Oral combination preparations are still approved and available today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates for healthy adult volunteers after oral administration of combination phenylephrine tablets (e.g., co-administered with antihistamines or paracetamol).</p><h4>References</h4><ol><li><p>Hendeles, L (1993). Selecting a decongestant. <i>Pharmacotherapy</i> 13(6 Pt 2) 129S–146S. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7507590/&quot;>https://pubmed.ncbi.nlm.nih.gov/7507590</a></p></li><li><p>Atkinson, HC, et al., &amp; Anderson, BJ (2015). Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review. <i>European journal of clinical pharmacology</i> 71(8) 931–938. DOI:<a href=&quot;https://doi.org/10.1007/s00228-015-1876-1&quot;>10.1007/s00228-015-1876-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26022219/&quot;>https://pubmed.ncbi.nlm.nih.gov/26022219</a></p></li><li><p>Janin, A, &amp; Monnet, J (2014). Bioavailability of paracetamol, phenylephrine hydrochloride and guaifenesin in a fixed-combination syrup versus an oral reference product. <i>The Journal of international medical research</i> 42(2) 347–359. DOI:<a href=&quot;https://doi.org/10.1177/0300060513503762&quot;>10.1177/0300060513503762</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24553480/&quot;>https://pubmed.ncbi.nlm.nih.gov/24553480</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R01BA53;
